NASDAQ:ARCT

Arcturus Therapeutics Holdings Stock News

etoro logo Buy ARCT
*Your capital is at risk
$7.60
-0.0500 (-0.654%)
At Close: Jun 03, 2026
SINGAPORE (Reuters) - Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.
The biotech’s CEO says vaccine’s efficacy data could come by Thanksgiving. Rival vaccine projects are getting big boosts.
Amid the race for a vaccine, Dexamethasone, a cheap and widely used steroid, has become the first drug to be able to save the lives of Covid-19 patients.
Singapore scientists testing a Covid-19 vaccine from US firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice. More than 100 vaccines are being deve
Global pandemic developments are also reported out of Brazil, Russia, India, Germany, Greece and other nations.
Investors who take an interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) should definitely note that the...
* EU countries agreed technical standards for interoperability between smartphone apps that track the risk of infections, a step that could help to revive travel and tourism. AMERICAS * The two most
Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.
More than 100 vaccines are being developed globally, including several already in human trials from the likes of AstraZeneca and Pfizer, to try and control a disease that has infected more than 8 mill
Testing using vaccine from US firm Arcturus Therapeutics is set to start in August.
Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.
Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.
"The most optimistic case is that it's about this time next year, that we will have a vaccine," Ooi said. Ooi is also working on a monoclonal antibody treatment for COVID-19 and will begin safety tri
Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Tuesday, BidAskClub reports. Other research ana
Singapore scientists to start human trials of COVID-19 vaccine in August
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE